Semapimod

Semapimod is a synthetic guanylhydrazone that has been studied for its potential use in the treatment of various inflammatory diseases and cancer. It was originally developed by Cytokine PharmaSciences, and has been licensed to other companies for further development.

Mechanism of action

Semapimod inhibits the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6), by macrophages. It also inhibits the activation of nuclear factor kappa B (NF-kappa B), a protein complex that controls the transcription of DNA and plays a key role in regulating the immune response to infection.

Clinical trials

Semapimod has undergone Phase II clinical trials for the treatment of Crohn's disease, rheumatoid arthritis, and psoriasis. In these trials, it was found to be well-tolerated and showed some evidence of efficacy, but further development has been halted due to lack of funding.

Potential uses

In addition to its potential use in inflammatory diseases, semapimod has also been studied for its potential use in cancer treatment. It has been shown to inhibit the growth of glioblastoma cells in vitro and in animal models, and a Phase I clinical trial has been conducted to evaluate its safety and efficacy in patients with recurrent glioblastoma.

See also

• Guanylhydrazone
• Cytokine PharmaSciences
• Inflammatory diseases
• Cancer

Semapimod Resources
Latest articles Most recent articles Ongoing trials	Wikipedia